Rating Rationale
July 08, 2020 | Mumbai
Baroque Pharmaceuticals Private Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.32.2 Crore
Long Term Rating CRISIL BBB-/Stable (Reaffirmed)
Short Term Rating CRISIL A3 (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its 'CRISIL BBB-/Stable/CRISIL A3' ratings on the bank facilities of Baroque Pharmaceuticals Private Limited (BPPL)
 
CRISIL ratings on the bank facilities of BPPLcontinues to reflect healthy profitability supported by established market position and above-average financial risk profile. These rating strengths are partially offset by a modest scale, and working capital-intensive nature, of operations.

Analytical Approach

For arriving at the ratings, CRISIL has combined the business and financial risk profiles of BPPL and Replica Pharmaceuticals Pvt Ltd (RPPL). That's because both these companies, together referred to as the Baroque group, have common promoters and management, and are engaged in similar lines of business. Also, both the companies are likely to be merged in FY21.

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation. 

Key Rating Drivers & Detailed Description
Strengths: 
* Healthy profitability supported by established market position
The group has healthy operating profitability which is estimated to be around 17% in FY20 which is supported by established market position of the company as the company's manufacturing facilities are WHO GMP certified and the company has conducted bio studies for various products which enables the company better pricing.
 
* Above-average financial risk profile
The networth and gearing were estimated to be moderate, at around Rs 60 crore and 0.4 time, respectively, as on March 31, 2020. The debt protection metrics were estimated to be strong, with interest coverage ratio is at 6.2 times and net cash accrual to total debt ratio at 0.5 time, for fiscal 2020. The financial risk profile is expected to remain above average over the medium term.  
 
Weaknesses:
* Modest scale of operations in a highly competitive industry
Despite steady growth, the total operating income remained modest estimated at Rs 80 crore in fiscal 2020, constrained by intense competition in the industry. The scale of operations should improve over the medium term supported by healthy growth in exports, but will remain modest due to increasing competition from other players in the sector.
 
* Working capital-intensive operations
Gross current assets have been high at around 220 days, mostly driven by estimated debtors of 120 days and inventory of over 50 days in fiscal 2020. Operations are likely to remain working capital intensive over the medium term.
Liquidity Adequate

Bank limit utilisation is moderate at around 60.26 percent for the past twelve months ended February 2020. Cash accrual are expected to be over Rs 7 Cr which are sufficient term debt obligation of Rs 3 Cr over the medium term. In addition, it will support incremental working capital requirements of the company. Current ratio is estimated to be moderate at around 1.6 times on March 31, 2020. The company has availed of moratorium for three months ended May 31, 2020, but has not extended it. The company has also applied for Covid-19 contingency funds for around 20% of the current facilities.

Outlook: Stable

CRISIL believes the Baroque group will continue to benefit from the extensive industry experience of its promoters, and maintain strong profitability over the medium term.

Rating Sensitivity factors
Upward factors
* Improvement is revenue and steady operating margin, leading to higher-than-expected cash accrual of over Rs 11 Cr
* Significant improvement in the working capital cycle
 
Downward factors
* Stretched working capital cycle, weakening the capital structure, with total outside liabilities to tangible networth ratio deteriorating to 2 times
* Further decline in operating profitability of the company
About the Group

Incorporated in 1994, BPPL is promoted by Mr. Jayanti Patel and family and is engaged in manufacturing of pharmaceutical formulations. The company has a manufacturing facilities in Khambhat, Gujarat.
 
Incorporated in 1994, Replica Remedies Private Limited (RRPL) is engaged in pharmaceutical formulation and is linked to BPPL as it shares common promoters and management. The company procures material from BPPL and trades.

Key Financial Indicators (Consolidated)
As on/for the period ended March 31   2019 2018
Operating income Rs crore 71.54 64.87
Reported profit after tax Rs crore 8.27 8.24
PAT margins % 11.56 12.70
Adjusted Debt/Adjusted Networth Times 0.55 0.60
Interest coverage Times 6.88 10.52

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments and are included (where applicable) in the Annexure -- Details of Instrument in this Rating Rationale. For more details on the CRISIL complexity levels, please visit www.crisil.com/complexity-levels.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon
Rate (%)
Maturity Date Issue Size
(Rs. Cr)
Complexity Levels Rating Assigned with Outlook
NA Bank Guarantee NA NA NA 1.5 NA CRISIL A3
NA Cash Credit* NA NA NA 12 NA CRISIL BBB-/Stable
NA Proposed Cash Credit Limit NA NA NA 2 NA CRISIL BBB-/Stable
NA Proposed Long Term Bank Loan Facility NA NA NA 2.67 NA CRISIL BBB-/Stable
NA Term Loan NA NA Jun-2023 14.03 NA CRISIL BBB-/Stable
*EPC/FBD/PCFC/EBR of Rs 12 crore is a sublimit of CC
 
Annexure - List of entities consolidated
Name of the company Extent of consolidation Rationale for Consolidation
Baroque Pharmaceuticals Private Limited Full Similar management and same line of business
Replica Remedies Private Limited Full Similar management and same line of business
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  30.70  CRISIL BBB-/Stable      28-06-19  CRISIL BBB-/Stable/ CRISIL A3      12-12-17  CRISIL BBB-/Stable  -- 
            30-03-19  Withdrawn(Issuer Not Cooperating)*           
Non Fund-based Bank Facilities  LT/ST  1.50  CRISIL A3      28-06-19  CRISIL A3      12-12-17  CRISIL A3  -- 
            30-03-19  Withdrawn(Issuer Not Cooperating)*           
All amounts are in Rs.Cr.
*Issuer did not cooperate; based on best-available information
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 1.5 CRISIL A3 Bank Guarantee 1.5 CRISIL A3
Cash Credit* 12 CRISIL BBB-/Stable Cash Credit* 12 CRISIL BBB-/Stable
Proposed Cash Credit Limit 2 CRISIL BBB-/Stable Derivatives Facility .5 CRISIL A3
Proposed Long Term Bank Loan Facility 2.67 CRISIL BBB-/Stable Proposed Long Term Bank Loan Facility 4.17 CRISIL BBB-/Stable
Term Loan 14.03 CRISIL BBB-/Stable Term Loan 14.03 CRISIL BBB-/Stable
Total 32.2 -- Total 32.2 --
*EPC/FBD/PCFC/EBR of Rs 12 crore is a sublimit of CC
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Approach to Recognising Default
CRISILs Bank Loan Ratings
CRISILs Criteria for Consolidation
CRISILs Criteria for rating short term debt
The Rating Process
Understanding CRISILs Ratings and Rating Scales

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Rahul Guha
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Neha Sharma
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 79 4024 4509
neha.sharma@crisil.com


Vaibhav Gupta
Rating Analyst - CRISIL Ratings
CRISIL Limited
B:+91 20 4018 1900
Vaibhav.Gupta@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL